Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.

Liu LL, Jiang Y, Wang LN, Yao L, Li ZL.

Drugs. 2012 Jul 30;72(11):1521-33. doi: 10.2165/11635030-000000000-00000. Review.

PMID:
22818016
2.

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.

Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H.

Nephrol Dial Transplant. 2007 Jul;22(7):1933-42. Epub 2007 Apr 3. Review.

PMID:
17405792
3.

Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.

Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A.

Medicine (Baltimore). 2010 Jul;89(4):227-35. doi: 10.1097/MD.0b013e3181e93d00. Review.

4.

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.

Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS.

Rheumatology (Oxford). 2009 Aug;48(8):944-52. doi: 10.1093/rheumatology/kep120. Epub 2009 Jun 3.

PMID:
19494179
5.

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB.

N Engl J Med. 2005 Nov 24;353(21):2219-28.

6.

Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.

Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC.

Am J Kidney Dis. 2013 Jan;61(1):74-87. doi: 10.1053/j.ajkd.2012.08.041. Epub 2012 Nov 22.

PMID:
23182601
7.

Treatment for lupus nephritis.

Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3. Review.

PMID:
23235592
8.

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.

Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR.

Clin J Am Soc Nephrol. 2007 Sep;2(5):968-75. Epub 2007 Aug 8. Review.

9.

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.

Lee YH, Woo JH, Choi SJ, Ji JD, Song GG.

Lupus. 2010 May;19(6):703-10. doi: 10.1177/0961203309357763. Epub 2010 Jan 11. Review.

PMID:
20064907
11.

Sequential therapies for proliferative lupus nephritis.

Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D.

N Engl J Med. 2004 Mar 4;350(10):971-80.

12.

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis.

Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS.

J Rheumatol. 2011 Jan;38(1):69-78. doi: 10.3899/jrheum.100130. Epub 2010 Oct 15. Review.

PMID:
20952473
13.

Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.

Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M.

Ann Intern Med. 2015 Jan 6;162(1):18-26. doi: 10.7326/M14-1030.

PMID:
25383558
14.

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N.

Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. Review.

15.

Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis.

Feng L, Deng J, Huo DM, Wu QY, Liao YH.

Nephrology (Carlton). 2013 Feb;18(2):104-10. doi: 10.1111/nep.12006. Review.

PMID:
23113811
16.

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group.

Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

17.
18.

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN.

N Engl J Med. 2000 Oct 19;343(16):1156-62.

19.

Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.

Burchardi C, Schlöndorff D.

Nat Clin Pract Nephrol. 2006 Jun;2(6):314-5. No abstract available.

PMID:
16932452
20.

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.

Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM.

Arthritis Res Ther. 2010;12(6):R208. doi: 10.1186/ar3184. Epub 2010 Nov 9.

Supplemental Content

Support Center